ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced financial results for its first quarter ended March 31, 2017, and provided an update on the Company’s pipeline, financial guidance and corporate restructuring.
As previously announced, following the decision by the United States District Court for the District of Delaware invalidating certain patents pertaining to AMPYRA®, Acorda implemented a corporate restructuring to reduce its cost structure and focus resources on its late-stage Parkinson’s disease programs, CVT-301 and tozadenant. The proposed brand name for CVT-301 is INBRIJA™ (levodopa inhalation powder). The Company expects to maintain exclusivity of AMPYRA at least through July 2018 and plans to appeal the ruling on the invalidated patents.
